1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Industry Analysis, August 2019

Healthcare Industry Analysis, August 2019

1-30 of about 200 reports

Alzheimer’s Disease: Update Bulletin #2 [April 2018]

Alzheimer’s Disease: Update Bulletin #2 [April 2018]

  • $ 1151
  • Industry report
  • April 2018

This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s ...

  • Industries : Mental Health, Therapy, Pathology
Market Access Impact: Renal Cell Carcinoma (EU5) 2018

Market Access Impact: Renal Cell Carcinoma (EU5) 2018

  • $ 5865
  • Industry report
  • April 2018

Market barriers affect 14 percent of RCC prescriptions in Europe. Is your brand losing out?Despite market barriers only affecting 14 percent of all renal cell carcinoma (RCC) prescriptions in Europe, certain ...

  • Industries : Cancer, Pathology
  • Countries : Europe
Ovarian Cancer: KOL Insight

Ovarian Cancer: KOL Insight

  • $ 9000
  • Industry report
  • April 2018

How will new combination regimens impact the ovarian cancer treatment landscape?PARP inhibitors are firmly entrenched in the treatment algorithm for ovarian cancer, and their role continues to diversify. ...

  • Industries : Therapy, Health Services, Medical Biotechnology
  • Countries : United States
Prostate Cancer: Update Bulletin #2 [April 2018]

Prostate Cancer: Update Bulletin #2 [April 2018]

  • $ 1151
  • Industry report
  • April 2018

Gain new key opinion leader (KOL) insights on the latest events happening in the prostate cancer space. Topics covered include expert opinions on the FDA approval of Johnson & Johnson’s (J&J’s) next-generation ...

  • Industries : Therapy
Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]

Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]

  • $ 1151
  • Industry report
  • April 2018

This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s ...

  • Industries : Mental Health, Therapy, Pathology
Market Access Impact: Renal Cell Carcinoma (US) 2018

Market Access Impact: Renal Cell Carcinoma (US) 2018

  • $ 5865
  • Industry report
  • April 2018

Market barriers only affect 8 percent of RCC prescriptions in the US. Is your brand losing out?Despite market barriers only affecting 8 percent of all renal cell carcinoma (RCC) prescriptions in the US, ...

  • Industries : Cancer
  • Countries : United States
Medical Affairs Reputations: Renal Cell Carcinoma (US) 2018

Medical Affairs Reputations: Renal Cell Carcinoma (US) 2018

  • $ 6948
  • Industry report
  • March 2018

In the US, nearly all of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 100 medical oncologists we polled say that each of those ...

  • Industries : Health Services
  • Countries : United States
Colorectal Cancer: Update Bulletin #2 [March 2018]

Colorectal Cancer: Update Bulletin #2 [March 2018]

  • $ 1151
  • Industry report
  • March 2018

Gain new key opinion leader (KOL) insights on the latest events happening in the CRC treatment landscapeTopics covered include expert opinions on; the potential of MabVax Therapeutics’ human antibody-based ...

  • Industries : Therapy, Oncology
Renal Cell Carcinoma: Update Bulletin #3 [March 2018]

Renal Cell Carcinoma: Update Bulletin #3 [March 2018]

  • $ 1151
  • Industry report
  • March 2018

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the success of Roche’s Phase III IMmotion151 trial of atezolizuma ...

  • Industries : Therapy, Cancer, Oncology, Pathology
Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2018

  • $ 6948
  • Industry report
  • March 2018

In the EU5, several of the renal cell carcinoma (RCC) medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team ...

  • Industries : Health Services
  • Countries : United Kingdom
NPS+ Haemophilia B (US) 2018

NPS+ Haemophilia B (US) 2018

  • $ 2924
  • Industry report
  • February 2018

Why are some US Haemophilia B brands standing out more than others?There are various options available to US haematologists treating haemophilia B. Clearly some of these options are achieving greater levels ...

  • Industries : Pathology
  • Countries : United States
Market Access Impact: Melanoma (EU5) 2018

Market Access Impact: Melanoma (EU5) 2018

  • $ 5865
  • Industry report
  • February 2018

Market barriers affect a fifth of melanoma prescriptions. Is your brand losing out?In the EU5, market barriers affect a fifth of all melanoma prescriptions, giving the top brand a narrow lead over two ...

  • Industries : Health Services
  • Countries : United Kingdom, United States
Bladder Cancer: Update Bulletin #2 [February 2018]

Bladder Cancer: Update Bulletin #2 [February 2018]

  • $ 1151
  • Industry report
  • February 2018

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase ...

  • Industries : Therapy
  • Countries : United States
Medical Affairs Reputations: Psoriasis (US) 2018

Medical Affairs Reputations: Psoriasis (US) 2018

  • $ 6948
  • Industry report
  • February 2018

Close rivalries among US psoriasis medical affairs teams. Will your team come out on top?In the US, nearly all of the psoriasis medical affairs teams we surveyed are running neck and neck with at least ...

  • Industries : Health Services
  • Countries : United States
NPS+ Haemophilia B (EU5) 2018

NPS+ Haemophilia B (EU5) 2018

  • $ 2924
  • Industry report
  • February 2018

Why are some EU5 Haemophilia B brands standing out more than others?There are various options available to EU5 haematologists treating haemophilia B. Clearly some of these options are achieving greate ...

  • Industries : Pathology
NPS+ Renal Cell Carcinoma (EU5) 2018

NPS+ Renal Cell Carcinoma (EU5) 2018

  • $ 2924
  • Industry report
  • February 2018

Why are some EU5 RCC brands standing out more than others?There are various options available to EU5 oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greate ...

  • Industries : Health Services
Targeted Therapies in Asthma: KOL Insight [2018]

Targeted Therapies in Asthma: KOL Insight [2018]

  • $ 9000
  • Industry report
  • February 2018

Can new biologics breathe fresh competition into the targeted asthma treatment landscape?The severe asthma treatment landscape is evolving. Near-term debates will focus on how best to use currently approved ...

  • Industries : Therapy, Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, North America, United Kingdom
NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]

NPS+ Hepatitis C Virus (HCV)Infection (EU5) [2018]

  • $ 2924
  • Industry report
  • February 2018

Why are some EU5 HCV brands standing out more than others?There are various options available to EU5 infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection ...

  • Industries : Pathology
Market Access Impact: Melanoma (US) 2018

Market Access Impact: Melanoma (US) 2018

  • $ 5865
  • Industry report
  • February 2018

Market barriers affect just under a fifth of melanoma prescriptions. Is your brand losing out?In the US, where market barriers affect just under a fifth of all melanoma prescriptions, the top brand has ...

  • Industries : Health Services
  • Countries : United States
Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (US) 2018

Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (US) 2018

  • $ 6948
  • Industry report
  • February 2018

Close rivalries among US NSCLC medical affairs teams. Will your team come out on top?In the US, nearly all of the NSCLC medical affairs teams we surveyed are running neck and neck with at least one rival. ...

  • Industries : Health Services
  • Countries : United States
NPS+ Renal Cell Carcinoma (US) 2018

NPS+ Renal Cell Carcinoma (US) 2018

  • $ 2924
  • Industry report
  • February 2018

Why are some US RCC brands standing out more than others?There are various options available to US oncologists to treat renal cell carcinoma (RCC). Clearly some of these options are achieving greater levels ...

  • Industries : Health Services
  • Countries : United States
Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018

Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018

  • $ 6948
  • Industry report
  • February 2018

Compare 11 NSCLC medical affairs teams. See how your team stacks up to the market leaderIn the EU5, several of the NSCLC medical affairs teams we surveyed are running neck and neck with at least one rival. ...

  • Industries : Health Services
Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2

Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2

  • $ 1151
  • Industry report
  • February 2018

This edition presents key opinion leader (KOL) views on recent developments in the non-small cell lung cancer (NSCLC) market. Topics covered include: the success of the Phase III KEYNOTE-189 trial of Merck ...

  • Industries : Therapy, Oncology
  • Countries : United States
NPS+ Hepatitis C Virus (HCV) Infection US [2018]

NPS+ Hepatitis C Virus (HCV) Infection US [2018]

  • $ 2924
  • Industry report
  • February 2018

Why are some US HCV brands standing out more than others?There are various options available to US infectious diseases specialists and primary care physicians (PCPs) treating hepatitis C virus infection ...

  • Industries : Pathology
  • Countries : United States
Prostate Cancer: Update Bulletin [January 2018]

Prostate Cancer: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the prostate cancer market. Topics covered include: Pfizer and Astellas’ announcement in September 2017 that the Phase III ...

  • Industries : Therapy, Cancer, Pharmaceutical
  • Countries : Europe
Pricing and Reimbursement in Neurology -- Payer views

Pricing and Reimbursement in Neurology -- Payer views

  • $ 2616
  • Industry report
  • January 2018

When first line treatments for neurological diseases such as Parkinson’s Disease (PD) and Multiple Sclerosis (MS) have been around for years, it’s understandable that when something new is approved, ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Alzheimer’s Disease: Update Bulletin [January 2018]

Alzheimer’s Disease: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in Alzheimer’s disease (AD) market, including; ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : World, North America, Europe
Ambitions in Health: Tech companies step up the pace

Ambitions in Health: Tech companies step up the pace

  • $ 792
  • Industry report
  • January 2018

As investment $$$ pour into digital health projects, the scope and scale of tech giants’ ambitions in health become ever clearer. From drug discovery and clinical research to patient monitoring and disease ...

  • Industries : Advanced IT
Ovarian Cancer: Update Bulletin [January 2018]

Ovarian Cancer: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the ovarian cancer market. Topics covered include: US Food and Drug Administration (FDA) acceptance for Genentech’s supplemental ...

  • Industries : Therapy, Oncology
  • Countries : United States
Psoriasis: Update Bulletin [January 2018]

Psoriasis: Update Bulletin [January 2018]

  • $ 1151
  • Industry report
  • January 2018

This edition presents key opinion leader (KOL) views on recent developments in the Psoriasis market. Topics covered include: Initiation of thePhase III BE VIVID trial for UCB’s bimekizumab (CDP-4940); ...

  • Industries : Pathology, Biotechnology
  • Countries : Europe, European Union
About 235000 reports

Download Unlimited Documents from Trusted Public Sources

Healthcare Industry Analysis in the US

  • August 2019
    40 pages
  • Pharmacy  

    Healthcare  

    Prescription Dr...  

  • United States  

    North America  

View report >

HIV AIDS Statistics August 2019

Diabetes Statistics August 2019

Diabetes Statistics August 2019


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on